Related Experiment Video
Updated: Jul 7, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Lipid lowering therapy for adults with diabetes
Leslie Jackowski1, Josephine Crockett, Debra Rowett
1Sansom Institute, University of South Australia. leslie.jackowski@unisa.edu.au
Australian Family Physician
|February 2, 2008
Summary
Diabetes prevalence in Australian adults has tripled, increasing cardiovascular disease (CVD) risk. Hyperlipidaemia is common in diabetes and a significant CVD risk factor.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Medicine
- Public Health
Background:
- Diabetes mellitus prevalence has tripled in Australian adults over 20 years.
- Cardiovascular disease (CVD) is the primary cause of death and illness in diabetic individuals.
- Hyperlipidaemia is a frequent comorbidity in diabetes and an independent risk factor for CVD.
Purpose of the Study:
- To highlight the escalating prevalence of diabetes in Australia.
- To underscore the link between diabetes, hyperlipidaemia, and cardiovascular disease.
- To emphasize the public health implications of managing diabetes and its associated risk factors.
Main Methods:
- Literature review and epidemiological data analysis.
- Analysis of trends in diabetes and cardiovascular disease incidence.
- Examination of the relationship between diabetes, hyperlipidaemia, and CVD risk factors.
Main Results:
- Significant increase in adult diabetes cases over the last two decades.
- Established diabetes as a major risk factor for cardiovascular disease.
- Confirmed hyperlipidaemia as a common and independent risk factor for CVD in diabetic patients.
Conclusions:
- Urgent public health strategies are needed to address the diabetes epidemic in Australia.
- Integrated management of diabetes and hyperlipidaemia is crucial for reducing cardiovascular morbidity and mortality.
- Further research into effective interventions for preventing CVD in diabetic populations is warranted.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...